2nd international conference on pharmscience research ... · daniele zink, nanobio lab (a*star),...

UNITED Scientific Group

A non-profit organization

VenueFour Points by SheratonLos Angeles International Airport9750 Airport BoulevardLos Angeles, CA 90045United States

2ndInternational Conference on

PharmScience Research & Development

PHAR

MA R

&D-2

020

Feb

rua

ry 2

4-26

, 20

20

Program Overview

February

24Monday

07:30-08:00 Registrations and Badge Pickup

08:00-10:00 Keynote Session

10:00-10:15 Networking Break

10:15-12:55 Session I: Drug

12:55-13:25 Networking Lunch & Group Photo




February

26Wednesday

08:00-10:00 Session-III: Pharma Industry


10:15-11:55 Session-III: Pharma Industry

11:55-12:55 Session-IV: Formulations & Mechanisms

12:55-13:25 Networking Lunch

13:25-16:25 Session-IV: Formulations & Mechanisms

16:05- Departures

February

25Tuesday

07:40-10:00 Session-II: Pharmacology



12:55-13:25 Networking Lunch & Poster Setup


16:05-16:20 Networking Break & Poster Setup


17:40-18:30 Poster Session

Keynote Session

08:00-08:30 The Therapeutic Potential of GABA(A)ergic Subtype Selective Ligands James M Cook, University of Wisconsin Milwaukee, Milwaukee, WI

08:30-09:00 Nanomedicine: The New Effective Approach to Fighting Antimicrobial and Chemotherapeutic Resistance

Thomas Webster, Northeastern University, Boston, MA

09:00-09:30 What Research & Development Can Do to Rapidly (and Successfully) Commercialize New Biopharmaceutical Products

Mark F. Witcher, Independent Consultant, Chapel Hill, NC

09:30-10:00 Metadichol®. One Process Many Diseases, One Approach Many Possible Cures P.R. Raghavan, Nanorx Inc, Chappaqua, NY


Session-I: Drug

Drug Discovery | Drug Design | Drug Development | Drug Delivery

Chairs: To be Updated

10:15-10:35 Changing the Paradigm of Drug Target Discovery using FFPE Specimens from Colorectal Cancer Patients and Adaptive Dynamic Artificial Polyligand Targeting

Heather O’Neill, Caris Life Sciences, Phoenix, AZ

10:35-10:55 Multi-Functional Small Molecules as Novel Therapeutics for a Rare Pediatric Neurodegenerative Disease

Paul C. Trippier, University of Nebraska Medical Center, Omaha, NE

10:55-11:15 De novo Designed Amphipathic α-Helical Antimicrobial Peptides to Treat the Gram-Negative Pathogen, Acinetobacter baumannii

Robert S Hodges, University of Colorado, Aurora, CO

11:15-11:35 Nano-Enabled Cancer Immunotherapy using Immunogenic cell death and Reversing Immune Checkpoints

Jianqin Lu, The University of Arizona Health Sciences, Tucson, AZ

DAY

1 February 24, 2020

Note: Last minute changes due to functional, private, or organizational needs can be necessary.The event organizer accepts no liability for any additional costs caused by a change of program. Program

is subject to change

11:35-11:55 Validation of DPAGT1 Inhibitors for Anticancer Chemotherapeutics Michio Kurosu, University of Tennessee Health Science Center, Memphis, TN

11:55-12:15 In Situ Visualization of the Phase Separation in Amorphous Solid Dispersion Luxi Li, Argonne National Laboratory, Lemont, IL

12:15-12:35 Structural and Biochemical Studies on Trimethoprim Resistant DHFR from Pathogenic Bacteria

Dennis L Wright, University of Connecticut, Storrs, CT

12:35-12:55 Redesigning Oral Drugs for Inhalation: Drug Delivery Along The Roads Less Traveled Gustavo R Rosania, University of Michigan, Ann Arbor, MI


13:25-13:45 Liposome-Based Parenteral Drug Lyophilization: Design Strategies and Regulatory Guidance

Yuwei Wang, California Health Sciences University, Fresno, CA

13:45-14:05 Oral Films A Multi Faceted Drug Delivery System and Dosage Form Bhaumik Patel, Cure Pharmaceuticals, Los Angeles, CA

14:05-14:25 Extracellular Vesicles as Payload Carriers for Targeted Drug Delivery Marjo Yliperttula, University of Helsinki, Finland

14:25-14:45 Early Probe Discovery in Academia Anuradha Roy, The University of Kansas, Lawrence, KS

14:45-15:05 Multifunctional Drugs from Protein Conjugates Kurt Vesterager Gothelf, Aarhus University, Denmark

15:05-15:25 On Demand Drug Delivery Technique for Retinal Diseases and Glaucoma Jong-Ki Kim, Catholic University of Daegu, South Korea

15:25-15:45 Pyrazolo[4,3-e][1,2,4]triazine as a Promising Scaffold for New Drugs Due to its Versatile Biological Behavior

Mariusz Mojzych, Siedlce University of Natural Sciences and Humanities, Poland

15:45-16:05 Platinum-Gold Bimetallic Nanoparticles in Anticancer Drug Delivery Moganavelli Singh, University of KwaZulu-Natal, South Africa


16:20-16:40 Synergic Killing Superbugs by a Phytochemical Carvacrol and Blu Light Mei X. Wu, Harvard University, Boston, MA

16:40-17:00 Site-Specific Chemical Conjugation of Antibody Using Affinity Peptide for Development of Innovative Antibody Medicines

Yuji Ito, Kagoshima University, Japan

17:00-17:20 Using Integrative Analysis of DNA Methylation and Gene Expression Data in Multiple Tissue Types to Prioritize Candidate Genes for Drug Development in Obesity

Kiang Wei Kho, Dublin City University, Ireland

17:20-17:40 Quorum Sensing Inhibitors as Pathoblockers for Pseudomonas aeruginosa Infections: A New Concept in Anti-Infective Drug Discovery

Martin Empting, Helmholtz-Institute f. Pharmaceutical research saarland (HIPS), Germany

Session-II: Pharmacology

Chairs: Guofeng You, Rutgers University, Piscataway, NJ Concettina La Motta, University of Pisa, Italy

07:40-08:00 Ibudilast: A Novel Therapy Targeting Adipokines that Induce Insulin Resistance Cynthia B. Jones, Marshall University, Huntington, WV

08:00-08:20 Role of Cerebral Blood Autoregulation in Alzheimer-Like Dementia in Diabetes Fan Fan, The University of Mississippi Medical Center, Jackson, MS

08:20-08:40 Preclinical Testing of ICA-1; A Potent Protein Kinase C-ι Inhibitor as a Potential Anticancer Drug

Mildred Acevedo Duncan, University of South Florida, Tampa, FL

08:40-09:00 New Targets for Anti-Inflammatory Therapeutics; An Understudied Mechanism for Regulating Vascular Inflammation

Neil Grimsey, University of Georgia, Athens, GA

09:00-09:20 Clinical Pharmacology Considerations of Bispecific Antibodies Ping Ji, Food and Drug Administration, Silver Spring, MD

09:20-09:40 Targeting Oncogene and Inflammation Pathways for Cancer Therapy Ruiwen Zhang, University of Houston, Houston, TX

09:40-10:00 Development of Isoform-Selective Protein Arginine Methyltransferase Inhibitors Y George Zheng, University of Georgia, Athens, GA


10:15-10:35 Drug Resistance in Mycobacterium tuberculosis and Targeting the L,D-Transpeptidase Enzyme

Kottayil I.Varughese, University of Arkansas for Medical Sciences, Little Rock, AR

10:35-10:55 Are There Limitations to Exercise Benefits in Peripheral Arterial Disease? Robert Lust, East Carolina University, Greenville, NC

10:55-11:15 Adeno-Associated Virus Delivery of Compounds for Analgesia: Targeting Dorsal Root Ganglia

Hongwei Yu, Medical College of Wisconsin, Milwaukee, WI

11:15-11:35 Molecular Mechanisms Underlying the Regulation of Drug Transporters Guofeng You, Rutgers University, Piscataway, NJ

11:35-11:55 Central versus Peripheral Sites of Action of New Ghrelin Agonists on Gastrointestinal Prokinetic Activity

Ehsan N. Mohammadi, University of Oklahoma Health Science Center, Oklahoma, OK

11:55-12:15 Evaluation of Commercially Available Meth-Deterrent Pseudoephedrine Products Ziyaur Rahman, Texas A&M University, College Station, TX

DAY

2 February 25, 2020

12:15-12:35 Inhibitor Design for CRIF1-CDK2 Interface: Unprecedented Strategy to Osteosarcoma Cell Proliferation

Sheng-Xiang Lin, Laval University, Canada

12:35-12:55 Effects of the Adipokinetic Hormone/Red Pigment-Concentrating Hormone (AKH/RPCH) Family of Peptides on Rat Schizophrenia Models

Oguz Mutlu, Kocaeli University Medical Faculty, Turkey

12:55-13:25 Networking Lunch & Poster Setup

13:25-13:45 Small Molecule Agonists of Glial Cell Line-Derived Neurotrophic Factor Receptor RET for Disease Modification in Parkinson’s Disease and Neuropathic Pain

Yulia Sidorova, University of Helsinki, Finland

13:45-14:05 Histamine Antagonists in the Kidney: May they Manage the Diabetic Nephropathy? Arianna Carolina Rosa, University of Turin, Italy

14:05-14:25 In-Silico Design and Biological Investigations of Diabetic Neuropathy Modulators: Could MOR Become a Focal Mediator for this Pathology?

Simone Ronsisvalle, University of Catania, Italy

14:25-14:45 Aldehyde Dehydrogenase Inhibitors: the Challenge to Defeat Cancer Stem Cells Concettina La Motta, University of Pisa, Italy

14:45-15:05 MDesign and Development of Dual Malate Dehydrogenase (MDH) 1/2 Inhibitors Targeting Cancer Metabolism

Minkyoung Kim, Dongguk University, South Korea

15:05-15:25 Efficient and Accurate Prediction of Human Organ Toxicities Daniele Zink, NanoBio Lab(A*STAR), Singapore

15:25-15:45 Effects of Antiepileptic Drugs on Spontaneous Recurrent Seizures in a Novel Model of Extended Hippocampal Kindling in Mice

Liang Zhang, Krembil Research Institute, Canada

15:45-16:05 The NIH Microphysiological Systems Program: Organs on Chips for Drug Efficacy and Toxicity Studies

Danilo A.Tagle,National Institutes of Health, Bethesda MD


16:20-16:40 Activity of Silver Nanoparticles on Prokaryotic Cells and Bothrops jararacussu Snake Venom

Isadora Caruso Fontana Oliveira, University of Sorocaba, Brazil

16:40-17:00 Efficacy of Aerosolized Rifaximin Versus Tobramycin for the Treatment of Pseudomonas aeruginosa Pneumonia in Mice

Roy Al Ahmar, Marshall University, Huntington, WV

17:00-17:20 Design and Synthesis of 1,2-Bis(hydroxymethyl)pyrrolo[2,1-a]phthalazine Hybrids as Potent Anticancer Agents that Inhibit Angiogenesis and Induce DNA Interstrand Cross-links

Tai-Ling Chen, China Medical University, Taiwan

17:20-17:40 Role of IL-1B and IL-6 in Antiarrhythmic Effect of Atrovastatin in Ouabain-Induced Arrhythmia in Rats

Azam Bakhtiarian, Tehran University of Medical Sciences, Iran

17:40-18:00 Targeting Non-coding RNAs for Cancer Therapy Yangchao Chen, The Chinese University of Hong Kong, Hong Kong

17:40-18:30 Poster Session

P-01 Reduce Cardiac Injury in Diabetes: GLP-1 Agonists, SGLT2 Inhibitors or Combination Therapy? Zhao Li, University of Saint Joseph, Hartford, CT

P-02 Further Studies on the Neuroprotective Actions of Hydrogen Sulfide and Cannabinoids in the Bovine Isolated Retina

Sunny E. Ohia, Texas Southern University, Houston, TX

P-03 Synthesis, Evaluation and Computational Simulations of Novel Pyrimidine Analogs as BRD4 Inhibitors

Haeil Park, Kangwon National University, South Korea

P-04 Skin Immunization with Third-Generation Hepatitis B Surface Antigen Using Microneedle Kim Jiseok, Gachon University, South Korea

P-05 A Comparison of Efficacy and Toxicity Profile According to Docetaxel, Platinum, Fluoropyrimidine Therapy in Advanced Gastric or Gastroesophageal Adenocarcinoma: Systematic Review and Meta-Analysis

Kyung Soo Kim,The Catholic University of Korea, South Korea

P-06 Isolation and Characterization and in vitro Test of Lytic Bacteriophages Against Antibiotic-Resistant Bacterial Strains of Pseudomonas aeruginosa

Liliam Harada, University of Sorocaba, Brazil

P-07 Microneedle for Intradermal Delivery of Botulinum Toxin A to Treat Palmar Hyperhidrosis Oh Yu Jeong, Gachon University, South Korea

P-08 The Antimicrobial Activity of Camel Lactoferrin Peptide Saleh Mohammed Saeed Alamri, Prince Sultan Military Medical City, Saudi Arabia

P-09 Lipidomic Analysis of the Effects of Melittin on Ovarian Cancer Cells Using Mass Spectrometry Sanad Alonezi, Prince Sultan Military Medical City, Saudi Arabia

P-10 The Preparation of Influenza Vaccine Microneedles Using Low Temperature Manufacturing Process

Shin Yu Ra, Gachon University, South Korea

P-11 Polymeric Nanocapsules Loaded with Phloretin: Antimelanoma Study and Development of New Semisolid Formulation

Talita P A Casarini, Federal University of Rio Grande do Sul, Brazil

P-12 Deflazacort-Induced Acneiform Eruptions Mohammed Shakeel Mohammed Bashir, Taif University, Saudi Arabia

P-13 Protective Effect of Curcumin in HepG2 Cells Against the Possible Cytotoxicity of drugs with activity antifibrotic (Doxazosin, Carvedilol and Tamsulosin)

Mariana Yazmin Medina-Pizaño, Universidad Autónoma de Aguascalientes, Mexico

P-14 Preliminary Research on Antitumor Effects of Atomic Carbon Jufeng Xia, New Japan Medical Institute, Japan

P-15 Antibacterial Efficacy of Hibiscus Extracts, Method Standardization for Studying Bioactive Compounds

Carmen Nava-Fischer, St. Philip’s CollegeSan Antonio, TX

Session-III: Pharma Industry

Analysis | Vigilance & RA | Case Studies


08:00-08:20 Real-World Evidence in Drug Development and Regulatory Submission Tze L Lai, Stanford University, Stanford, CA

08:20-08:40 Rapid Development of New Biopharmaceutical Products Using a Multi-Purpose Manufacturing Facility

Mark F. Witcher, Independent Consultant, Chapel Hill, NC

08:40-09:00 Using a Surrogate Marker for Early Testing of a Treatment Effect Layla Parast, RAND Corporation, Santa Monica, CA

09:00-09:20 Characterization of Protein and Silicone Particles in Therapeutic Formulations Using Imaging Flow Cytometry

Christine Probst, Luminex Corporation, Seattle, WA

09:20-09:40 The Certainty in Consumers Willingness to Accept Pharmacist Provided Medication Therapy Management Services

Lawrence “LB” Brown, Chapman University, Irvine, CA

09:40-10:00 A Novel Method using Nuclear Magnetic Resonance for Plasma Protein Binding Assessment in Drug Discovery Programs

Daniel Oscar Cicero, University of Rome Tor Vergata, Italy


10:15-10:35 A Case Study in Identifying Targeted Patients Population in Major Depressive Disorder by Enhanced Enrichment Design

Peter Zhang, Otsuka Pharmaceutical Development & Commercialization, Inc., Princeton, NJ

10:35-10:55 Relative Group Contribution (RGC) Model as an Innovative Strategy for the Rescue of Small-Molecule Fragments in Drug Discovery

Andres Felipe Vasquez, Universidad de los Andes, Colombia

10:55-11:15 Adverse Drug Reaction Profile in Amravati Region of India- A Pharmacovigilance Study Mohammed Shakeel Mohammed Bashir,Taif University, Saudi Arabia

11:15-11:35 A Case Study in Addressing CHMP Major Objections in Efficacy to Achieve Registration Approval

John Ouyang, Otsuka Development & Commercialization Inc., Rockville, MD

11:35-11:55 Genotypic Characterization of Pseudomonas aeruginosa Isolates from Turkish Children with Cystic Fibrosis

Dicle Sener Okur, Istanbul University, Turkey

DAY

3 February 26, 2020

Session-IV: Formulations & Mechanisms

Natural Compounds | Nanomedicine | Personlized Medicine | Biopharmaceutics


11:55-12:15 Pediatric Oral Formulations: An Updated Review of Commercially Available Pediatric Oral Formulations Since 2007

Robert G. Strickley, Pliant Therapeutics, San Francisco, CA

12:15-12:35 Evaluation of Anti Obesity Activity of Ethanolic Extract ofx1 Degener Leaves in 3T3- L1 Cell Lines

Jinitha Anu Saji, Caritas College of Pharmacy, India

12:35-12:55 Litogenolitic and Solubility Properties of Products Obtained from Common Ivy Extract (Hederae helicis e folium) and Medium of Diversified Polarity (ƐM)

Elzbieta Nowak, Europlant Group, Poland


13:25-13:45 Rapid Development of Nano-Formulations from Screening to Production Combining Dual Centrifugation DELTAVITA 1 and Wet Agitator Bead Milling

Dan Galvin, NETZSCH Premier Technologies, LLC., Exton, PA

13:45-14:05 Modeling Clearance of Immune Checkpoint Inhibitors as a Potential Biomarker for Drug Resistance in Mice

Mitch Phelps, The Ohio State University, Powell, OH

14:05-14:25 Innovative Technologies for Drying of Moist Porous Media Jamal Yagoobi, Worcester Polytechnic Institute, Worcester, MA

14:25-14:45 A New Mouthrinse Formula for Long Term Maintenance of Oral Hygiene Stephen Connelly, University of California, San Francisco, CA

14:45-15:05 Personalized and Precision Effects of Chinese Medicine: A New System Approach on the Studies of in vivo Prescription Compatibility in Formula Concoction

Steven LOH Cheng Toa, Nanyang Technological University, Singapore

15:05-15:25 Structural Exploration of Different Binding Pockets Suitable to Affect Protein Kinase CK2 with Peptides and Small Molecules

Dirk Lindenblatt, University of Cologne, Germany

15:25-15:45 Total Antioxidant Status in Sapropel Extracts Layer by Layer Aneka Klavina, Rigas Stradinš University, Latvia

15:45-16:05 Chlorophyllin Derivatives Mediated PDT: In Vitro and In Vivo Approaches for Targeted Therapy

Iman Gomaa, October University for Modern Sciences and Arts, Egypt

16:05- Departures

Note: Last minute changes due to functional, private, or organizational needs can be necessary.The event organizer accepts no liability for any additional costs caused by a change of program. Program

is subject to change

United Scientific Group (A Non-profit Organization)

# 8105, Rasor Blvd - Suite #112, PLANO, TX 75024

Ph: +1-469-854-2280/81; Toll Free: +1-844-395-4102; Fax: +1-469-854-2278

Email: [email protected]

Web: https://pharma-rd.com/

We wish to see you in

Los Angeles, CA

Pharma R&D-2020

2nd international conference on pharmscience research ... · daniele zink, nanobio lab (a*star),...

Documents